BINEX Co (053030) Fair Value & Analysis
Healthcare · KR · Market cap 206B KRW
Fair value as of: Aug 13, 2026
From 4 valuation models · updated yesterday
Share price +4.8% over the past month.
A solid business, but screening 74% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (2,895 KRW). The favourable scenario is already priced in.
- The model range is unusually wide (794.01 KRW to 2,895 KRW). The outcome hinges heavily on assumptions, so read the point estimate with caution.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- Solid but not exceptional quality (56/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range 5,940 KRW – 32,250 KRW · fair‑value band 794.01 KRW – 2,895 KRW · the 7,220 KRW price screens above the 1,844 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
BINEX Co (053030) currently trades at 7,220 KRW, while our model-based Fair Value estimate is 1,844 KRW, implying the stock looks roughly 74.5% overvalued today. The Quality Score stands at 56/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, BINEX Co generated revenue of 155B KRW at a net margin of 10.7%. Revenue grew 18.3% year over year. Net debt stands at 73.5B KRW. Fundamentals as of Aug 13, 2026
Our scenario range runs from 794.01 KRW (bear case) to 2,895 KRW (bull case); at 7,220 KRW, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 62% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -11% fair-value upside, at -74%, 053030 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 4 models by family
Widest divergence: Asset-Based (4,024 KRW) versus Dividend Discount (330.94 KRW). Highest evidence: Gordon GGM (70).
Notify me when 053030 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 52 · Market factors (momentum, volatility) 18
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
BINEX Co., Ltd. operates as a pharmaceutical company in South Korea. It offers bisroot products; GI tract and antispasmodic, and antiulcer agents; NSAIDs; cardiovascular and urology products; hepatic protectors; ointments and creams; ophthalmic solutions; CNS agents; digestive products; constipation and blood circulation products; antibiotic and antifungal …
Full company description
BINEX Co., Ltd. operates as a pharmaceutical company in South Korea. It offers bisroot products; GI tract and antispasmodic, and antiulcer agents; NSAIDs; cardiovascular and urology products; hepatic protectors; ointments and creams; ophthalmic solutions; CNS agents; digestive products; constipation and blood circulation products; antibiotic and antifungal agents; cough and cold remedy products; vitamins and nutrients; antihistamine products; antivertigo products; and OTC products. BINEX Co., Ltd. has a co-development partnership with Genexine, Inc. to develop COVID-19 vaccine. The company was founded in 1957 and is based in Incheon, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
BINEX Co reported revenue of 168B KRW in FY2025 versus 134B KRW in FY2021, a compound +5.8%/yr. Reported net income was −3.2B KRW in FY2025.
053030 screens 74% overvalued. Compare with Torrent Pharmaceuticals Limited →
Peer Group
Pharmaceuticals · 25 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Pharmaceuticals stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Torrent Pharmaceuticals Limited 500420 | ₹4,876 | ₹4,360 | -11% |
| GlaxoSmithKline Pharmaceuticals Limited 500660 | ₹2,620 | ₹1,452 | -45% |
| Caregen Co 214370 | 64,400 KRW | 7,277 KRW | -89% |
| ST Pharm Co 237690 | 107,000 KRW | 50,110 KRW | -53% |
| Oscotec Inc 039200 | 38,800 KRW | 33,210 KRW | -14% |
| DongKook Pharmaceutical Co 086450 | 21,600 KRW | 31,283 KRW | +45% |
| Kolon Life Science Inc 102940 | 17,460 KRW | 37,129 KRW | +113% |
| Huons Global Co 084110 | 25,100 KRW | 58,482 KRW | +133% |
| Anterogen.Co.,Ltd., a bio-venture company, 065660 | 15,520 KRW | 4,741 KRW | -69% |
| Kyung Dong Pharmaceutical Co 011040 | 5,180 KRW | 6,165 KRW | +19% |
Compare BINEX Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is BINEX Co (053030) overvalued or undervalued?
What is the fair value of 053030?
What is the quality score of 053030?
What is the revenue of BINEX Co (053030)?
What is the net profit margin of 053030?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track BINEX Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.